Skip Navigation


Annals of Oncology Advance Access originally published online on October 19, 2007
Annals of Oncology 2007 18(12):2006-2008; doi:10.1093/annonc/mdm357
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
18/12/2006    most recent
mdm357v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Asmis, T. R.
Right arrow Articles by Shah, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Asmis, T. R.
Right arrow Articles by Shah, M. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

gastrointestinal tumors

Systemic chemotherapy does not increase the risk of gastrointestinal perforation

T. R. Asmis, M. Capanu, D. P. Kelsen and M. A. Shah*

Memorial Sloan Kettering Cancer Center, New York, USA

* Correspondence to: Dr Manish A. Shah, Memorial Sloan Kettering Cancer Center, Gastrointestinal Oncology, 1275 York Avenue, Howard 910, New York, NY, 10021, USA. Tel: +1–212–639–3113; Fax: +1–212–717–3342; E-mail: Shah1{at}mskcc.org.

Background: Gastrointestinal perforation is a rare complication of gastric cancer. Although there is the perception of chemotherapy aggravating the perforation risk, the rate of perforation in patients with gastric cancer receiving chemotherapy is unknown. This study describes the incidence and clinical course of patients with gastric or gastroesophageal junction (GEJ) carcinoma who experience a perforation while receiving chemotherapy.

Patients and methods: The records of patients with gastric or GEJ adenocarcinoma over a 6-year period who received chemotherapy for locally advanced or metastatic disease were reviewed. Extracted information included demographics, treatment received, and overall survival was calculated.

Results: 1032 patients at MSKCC received systemic cytotoxic chemotherapy for locally advanced or metastatic gastric or GEJ carcinoma; 11 patients experienced a perforation (1.1%, 95% CI 0.5–1.9%); 5/11 (45%) patients received further chemotherapy and had a median survival of 5.6 months.

Conclusions: The rate of perforation in patients with advanced GEJ/gastric adenocarcinoma receiving chemotherapy is 1.1%, which is the same rate as in surgical series of patients presenting with perforation. Chemotherapy does not significantly add to the risk of gastrointestinal perforation.

Key words: gastric /gastroesophageal adenocarcinoma, preoperative chemotherapy, perforation, surgery

Received for publication May 15, 2007. Revision received June 8, 2007. Revision received June 12, 2007. Accepted for publication June 13, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.